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ABSTRACT 
 Age is a primary risk factor for chronic conditions including cardiovascular diseases. 
With inflation in the aged population over the last century, there is a growing need for 
interventions that directly target aging.  Acarbose, an alpha-glucosidase inhibitor, is a promising 
aging intervention that increases lifespan in male and female mice by 22% and 5%, respectively 
(Harrison, 2013). Acarbose is an FDA approved anti-diabetic drug with a limited side effect 
profile. However, it has not been established if Acarbose has beneficial effects on healthspan or 
measures of functional health. We hypothesized that, in addition to lengthening lifespan, 
Acarbose would also diminish the effects of aging on motor and cardiac function. 
 Using an outbred mouse model with young control, old control, and old Acarbose treated 
mice, motor function testing demonstrated a decline in functional health with age that was 
ameliorated by Acarbose treatment. Echocardiography showed concentric left ventricular 
hypertrophy with age in both males and females that was abrogated with Acarbose treatment in 
males. However, no significant declines in cardiac function were detected with age nor were any 
effects of Acarbose observed on cardiac function. 
 Preliminary mass spectrometry analysis suggested that metabolism could play a role in 
the cardiac aging process, but no evidence suggested a role of Acarbose in reversing these age-
related changes. An ELISA based assay (PROCISE) also demonstrated a reduction in 
constitutive proteasome activity in the heart with age, but this was not affected by Acarbose. 
 The findings that Acarbose ameliorates some functional declines seen with age and 
abrogates left ventricular hypertrophy in males furthers its promise as an aging intervention, but 
more research is needed into its effects in the heart and other physiological systems before it 
could serve as a clinically relevant drug for non-diabetic patients. 
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INTRODUCTION 
Burdens of an Aging Population – Healthspan and Lifespan 
 Advancements in public health as well as medical interventions have significantly 
increased the median lifespan of individuals in society (Wright and Weinstein, 1998). The 
United States in particular is experiencing drastic growth in its population of people 65 years and 
older, to the extent that these individuals are anticipated to comprise 20% of the overall 
population by the year 2023 (Arias, 2014). Aging is a risk factor for many chronic diseases 
including neurodegenerative diseases, cancer, and cardiovascular diseases (Partridge, 2010), the 
latter representing the leading causes of death around the world (World, 2014). Therefore, with 
more people living longer lives, chronic diseases and their burden will become increasingly 
prevalent, necessitating advancements in healthcare treatment strategies. Maintenance of cardiac 
health is a key focus of these healthcare strategies, as it is an essential component to lifespan 
(Quarles, 2015) and also healthspan (Lakatta, 2003), which refers to the period in one’s life when 
general health and function is maintained. Extending healthspan, instead of just focusing on 
lifespan, has become a greater clinical and research focus, as delaying or preventing disease and 
disability can facilitate a healthier life with aging (Living, 2015). 
 
Motor Function 
 One of the most obvious declines in healthspan for an elderly patient is impairments in 
motor function. Not being able to perform everyday tasks like getting out of bed, walking to the 
bathroom, and preparing meals can pose a large burden on someone’s life. There are numerous 
tests that physicians and physical therapists utilize in order to assess the levels of functional 
disability in an aged patient. One commonly used test referred to as the “timed up and go test” 
requires the individual to stand from sitting in a normal arm chair, walk to an imaginary finish 
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line 10 feet away, walk back to the chair, and sit back down as quickly as possible. Longer times 
on this test are predictive of a higher risk of falling for the patient. A similar test also used for 
geriatric patients is the “sit-to-stand test,” which measures the time required for the individual to 
stand from a normal arm chair and return to a sitting position a total of 5 consecutive times. 
Another assessment of disability involves asking the patient to perform a squat and observing the 
smoothness of the movements and muscle contractions and relaxations. Together, these kinds of 
tests model everyday movements and abilities that are important for an individual’s quality of 
life. They all show marked declines in performance with age, and reduced ability at these skills 
are predictive of other comorbidities associated with aging such as falling (Gellert). 
 
The Cardiac Aging Phenotype 
 Healthspan parameters also often include elements of cardiac health, and changes in the 
heart with age that are indicative or predictive of dysfunction have been established. These kinds 
of variables are essential in not only diagnosing impairments in the heart, but also in measuring 
the effectiveness of treatment strategies at ameliorating age-related changes. There are several 
key features, both structural and functional, that typically distinguish an old from a young heart. 
In terms of cardiac structure, aging is associated with hypertrophy of the left ventricle, the largest 
chamber of the heart that is responsible for pumping blood throughout the body. More 
specifically, cardiac aging usually leads to concentric hypertrophy, in which there is thickening 
of the walls of the left ventricle and the cavity size is either reduced or shows no significant 
changes. When it comes to age-related functional changes in the heart, there are often 
impairments in diastolic function, which is the ability of the heart to properly relax following a 
contraction. However, the contractile ability of the heart, referred to as systolic function, is 
typically maintained with age (Fleg, 2012). 
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Directly Targeting Aging 
 Motor function and cardiac health are important measures of healthspan that decline with 
age, but aging-associated comorbities are countless and occur all throughout the body. This 
means that treatment strategies targeting individual physiological systems could grow 
impractical as more and more markers of dysfunction appear. Therefore, there is an increasing 
amount of research going into interventions that target aging directly instead of targeting 
individual diseases or symptoms. The ideal intervention would not only extend lifespan, but also 
improve a variety of healthspan measures that are critical to overall quality of life. 
 Two of the most well characterized aging interventions are caloric restriction, which is 
typically defined as consuming approximately 70% of one’s normal caloric intake, and 
rapamycin, an immunosuppressant compound. Both caloric restriction (Flurkey, 2010) and 
rapamycin (Harrison, 2010) have been shown to significantly extend lifespan in male and female 
mice. It has also been demonstrated that both interventions lead to improvements in motor 
function (Salvatore, 2016; Zhang, 2014) in addition to reversing several cardiac structural and 
functional changes seen with aging (Dhahbi, 2006; Dai, 2014). The mechanism of lifespan 
extension for both interventions involves inhibition of the kinase mTOR, or mammalian target of 
rapamycin. mTOR signaling integrates intracellular and extracellular signals and serves as a key 
regulator of cell proliferation, growth, metabolism, and survival (Laplante, 2009). While the 
lifespan and healthspan improvements of caloric restriction and rapamycin are well documented 
in model organisms, the clinical applicability of them as potential aging interventions in humans 
is limited. Rapamycin can be accompanied by several adverse effects, including metabolic 
complications, immunosuppression and infectious complications, and pulmonary and renal 
toxicities (Somers, 2015). Caloric restriction may be considered a safer intervention, albeit with 
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potential for nutritional deficiencies in older adults (Miller, 2008), but adhering to such a 
regimen is exceedingly difficult and considered impractical (Johnson, 2011). An exploration of 
new potential interventions in the aging process that have greater clinical relevance is therefore 
needed. 
 
Acarbose as a Promising Aging Intervention 
 A new compound entered the conversation of potential aging interventions in 2014 when 
Acarbose was shown to significantly increase lifespan in male (22%) and female (5%) mice, 
with greater improvement in males than females (Harrison, 2014). Importantly, Acarbose is a 
well-tolerated drug with minimal gastrointestinal side effects prescribed for diabetic patients 
(Hollander, 1992). Acarbose therefore arguably has greater translational value than caloric 
restriction or rapamycin as an aging intervention, yet the effects of Acarbose on healthspan have 
not been assessed. The compound is an intestinal alpha-glucosidase inhibitor, preventing the 
breakdown of polysaccharides into glucose and limiting glucose absorption from the GI tract. 
Acarbose was first theorized to potentially work as an aging intervention based on its ability to 
prevent postprandial hyperglycemia, which has been suggested to contribute to aging (Archer, 
2003). Furthermore, based on its gastrointestinal role of limiting glucose absorption, Acarbose 
could also be thought of as a plausible calorie restriction mimetic (Harrison, 2014). This implies 
that Acarbose may also inhibit mTOR signaling and extend lifespan through a similar molecular 
mechanism to caloric restriction and rapamycin. The possible connection between Acarbose and 
mTOR signaling could also be explained based on the impact of Acarbose on insulin-like growth 
factor (IGF) signaling. It has been demonstrated that Acarbose reduces IGF-1 levels (Harrison, 
2014) and that IGF signaling is interconnected with mTOR complex 1 (mTORC1) through 
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several molecular mediators including FOXO transcription factors phosphatidylinositol-3-OH 
kinase (PI(3)K) and Akt kinase (Johnson, 2013). Therefore, if Acarbose is extending lifespan 
through similar molecular processes to rapamycin and caloric restriction, it can be hypothesized 
that Acarbose may also lead to similar improvements in healthspan measures of motor and 
cardiac function. Determining if Acarbose can successfully improve healthspan is essential in 
analyzing its potential as an aging intervention in humans. This ultimately leads to the overall 
goal of this thesis research: to investigate the effects of Acarbose on age-associated declines in 
motor and cardiac function and dissect the molecular mechanisms through which Acarbose 
impacts the aging process. 
 
 
 
 
 
 
 
 
B A 
Figure 1. Kaplan-Meier survival plot demonstrating that Acarbose significantly extends lifespan in both 
male and female mice. Lifespan extension in males (A) is more significant than in females (B). Adapted 
from Harrison et al., 2014. 
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Outbred Mouse Model Study Design 
 A plethora of model organisms have been used in aging research, but some of the most 
ubiquitous include yeast, roundworms, fruit flies, and mice. While they have disadvantages 
regarding cost and time investment, mice were used for this study based on the ease and clinical 
relevance of obtaining measures of motor function, cardiac function, and cardiac tissue for 
molecular analysis from the model. More specifically, an outbred mouse strain was utilized to 
best model human genetic heterogeneity. Control 4-month-old mice, control 22-month-old mice, 
and Acarbose treated 22-month-old mice were used for this study to delineate the effects of both 
age and Acarbose on measures of healthspan and relevant molecular pathways. 
 
Motor Function Testing in a Mouse Model 
 To evaluate the ability of Acarbose to improve elements of motor function in mice, a 
series of mouse-specific functional tests were performed that demonstrate age-related declines in 
a mouse model and that are translationally relevant measures in humans. One such measure is 
forelimb grip strength, which has been shown to significantly decline with age in mice (Justice, 
2013). Grip strength is also considered a clinically useful parameter, as poorer grip strength has 
been shown to be associated with increased mortality from all-causes, from cardiovascular 
disease, and from cancer in men (Gale, 2007). Several protocols for measuring functional health 
in mice have also been established using a rotarod, which is an electrically controlled spinning 
rod on which mice walk or run. A rotarod acceleration test, which serves as a measure of balance 
and coordination, has shown significant declines in performance in aged mice, similar to grip 
strength (Justice, 2013). A rotarod endurance test, which represents a form of exercise 
performance, has also demonstrated reduced endurance in mice with aging (Justice, 2013). Both 
coordination and exercise performance are important in human functional health. Therefore, grip 
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strength and rotarod testing serve as clinically relevant measures of healthspan that show age-
associated declines in mice and can be used to test the effects of Acarbose on functional health. 
 
 
 
 
 
 
 
 
 
 
Mouse Echocardiography 
 Measuring changes in cardiac structure and function in human patients is often performed 
using echocardiography, a form of ultrasound imaging. This technique can also be utilized with 
mice and therefore serves as a valuable tool to assess the impacts of age and Acarbose on cardiac 
health. One form of echocardiography, often referred to as conventional echocardiography, can 
provide structural measures such as left ventricular mass and chamber wall thicknesses in 
addition to some functional parameters like ejection fraction (a systolic measure of the 
percentage of blood leaving the heart each time it contracts). Additional forms of ultrasound 
imaging include Pulsed Wave Doppler and Tissue Doppler echocardiography which measure 
velocities of the valves and muscles of the heart as well as functional time intervals during 
contraction and relaxation. One frequently analyzed Doppler measurement is isovolumic 
relaxation time (IVRT), which is the time between the closure of the aortic valve and the opening 
A B 
Figure 2. Depictions of grip strength (A) and rotarod (B) tests performed on experimental mice. 
Adapted from Justice et al., 2013. 
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of the mitral valve. This interval reflects the time between the end of a contraction and the 
beginning of relaxation of the heart, therefore making it an indicator of cardiac diastolic function. 
Another useful diastolic variable is the ratio of early to late left ventricular filling, or E’/A’. The 
early filling variable E’ reflects the velocity of blood as it passively flows into the left ventricle 
during diastole. The late filling variable A’ is the velocity of blood that is forced into the left 
ventricle at the beginning of systole prior to ventricular contraction. This parameter is therefore 
affected by changes in the heart’s diastolic ability to allow blood to passively flow into the 
ventricle. An additional variable often measured with Doppler echocardiography is Myocardial 
Performance Index (MPI), a combinatorial measure of systolic and diastolic function that 
considers the times required for left ventricular contraction, relaxation, and ejection. 
 Echocardiography in mice has revealed that many of the key features of human cardiac 
aging can be recapitulated in a mouse model. In mice, increased left ventricular mass has been 
demonstrated with age (Dai, 2009). Increased IVRT, indicating diastolic dysfunction, has also 
been shown in an aged mouse model (Qin, 2013). Mice have also been shown to have 
significantly reduced E’/A’ ratios, signifying a decline in diastolic function, in addition to 
increased MPI with age, indicative of a worsening of overall cardiac function (Dai, 2009). This 
suggests that conventional and Doppler echocardiography can detect age-related declines in 
cardiac structure and function in mice and could potentially also detect any Acarbose-induced 
changes as well. 
 Another form of imaging that has been suggested to be a more sensitive measure of 
cardiac function is strain echocardiography. Strain uses motion tracking to detect subtle changes 
in the length of the left ventricular wall during contraction and relaxation, serving as a measure 
of tissue deformation throughout the cardiac cycle. The outputs of strain echocardiography are 
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measures of strain, in percent change of left ventricular wall length, and strain rate, in percent 
change of wall length per second. Measures are obtained from 2 different planes of view: short 
axis (from the left to right side of the heart) and long axis (from the base to the apex). Short axis 
imaging provides measures of radial and circumferential strain and strain rate, whereas long axis 
provides measures of radial and longitudinal strain and strain rate. Radial strain measures tissue 
deformation in the left-to-right orientation of the heart, longitudinal strain measures deformation 
in the base-to-apex orientation, and circumferential strain measures rotational deformation of the 
ventricle. 
 Strain echocardiography has also been performed in mice and demonstrated age-
associated impairments. Slightly decreased measures of strain and strain rate were found in the 
radial, circumferential, and longitudinal directions, suggesting an overall decline in contractile 
function. The aging intervention rapamycin was also tested in these mice, and treatment led to 
selective improvements in some strain parameters. Age-related declines in circumferential strain 
and strain rate were ameliorated with rapamycin, while all other measures were unaffected 
(Flynn, 2013). Being a more sensitive measure of cardiac function, strain serves as an additional 
tool to detect functional changes with age or Acarbose that may be too subtle to detect with 
conventional or Doppler echocardiography. 
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Investigating Molecular Pathways with Mass Spectrometry 
 As previously discussed, there is reason to believe that Acarbose could interact with 
mTOR signaling to impact the aging process. However, it is also possible that the link between 
Acarbose and aging could be explained by changes in metabolic efficiency. It is known that in 
the normal adult heart, fatty acid oxidation is responsible for the majority of ATP production. 
However, under pathological conditions such as hypertrophy, the main fuel for energy 
production in the heart shifts to glucose (Ma, 2015), demonstrating a reduction in metabolic 
efficiency. Based on the hypertrophic signature of the aged heart, it would be expected that this 
shift in energy metabolism would also occur with aging. 
 Because of the potential link between cardiac metabolism and aging, the impact of 
rapamycin on metabolic efficiency has been investigated in aged mice. Consistent with an 
improvement in the metabolic profile of the heart to a youthful state, rapamycin was shown to 
A B 
Figure 3. Diagrams to help illustrate the short-axis and long-axis views of the heart in strain 
echocardiography (A) in addition to the orientations of radial, longitudinal, and circumferential strain of 
the left ventricle of the heart (B). Adapted from Gonzalez, 2009 (A) and Malik et al., 2016 (B). 
Louzon 14 
 
decrease the levels of 4 glycolytic intermediates, indicative of a reduction in glycolysis. This 
finding was accompanied by an increase in TCA cycle intermediates that serve as entry points of 
anaplerosis (Chiao, 2016), also suggestive of an improvement in metabolic efficiency with 
rapamycin.  
 In addition to the possibility that Acarbose may function through a similar molecular 
mechanism to rapamycin, the direct role of Acarbose in carbohydrate metabolism suggests that it 
may also restore the heart to a healthier metabolic state. By acting as an alpha-glucosidase 
inhibitor, Acarbose decreases the levels of free circulating glucose in the body. It is possible that 
this would therefore lead to a decrease in glucose utilization through a reduction in glycolysis in 
various organ systems, including the heart, leading to greater metabolic efficiency. 
 The role of Acarbose in aging could be explained by an interaction with mTOR signaling, 
by improvements in cardiac metabolic efficiency, a combination of the two, or through any 
combination of previously unpredicted mechanisms. Therefore, unbiased mass spectrometry was 
performed in the hopes of elucidating the molecular changes seen in the heart with age and with 
Acarbose treatment. 
 
Aging and Proteostasis 
 In addition to an unbiased study with mass spectrometry, a specific molecular process 
investigated was proteostasis, which refers to the maintenance of protein quality control 
mechanisms including synthesis, degradation, folding, and trafficking.  Proteostasis underlies 
many forms of dysfunction throughout the body, and there are several diseases that are 
associated with deficits in proteostasis including Creutzfeldt-Jakob disease, Alzheimer’s disease, 
Parkinson’s disease, and many more. Impaired protein homeostasis is also a hallmark of aging 
(López-Otín, 2013). The induced synthesis of cytosolic and organelle-specific chaperones during 
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stress is greatly impaired with age (Calderwood, 2009). Long-lived mouse strains show a marked 
upregulation of some heat-shock proteins (Swindell, 2009). Amyloid-binding compounds can 
help maintain proteostasis during aging and extend lifespan (Alavez, 2011). The activities of the 
authophagy-lysosomal system (Rubinsztein, 2011) and the ubiquitin-proteasome system 
(Tomaru, 2012), two key proteolytic systems in protein quality control, also have been shown to 
decline in aging. Given this, it is possible that impairments in proteostasis could underlie some 
aspects of cardiac dysfunction seen with age. 
 A key component to proteostasis is the controlled expression and activity of proteasomes, 
which are protein complexes that function to degrade misfolded, damaged, or unneeded proteins 
through proteolysis. Proteasomes are cylindrical complexes made up of stacked rings of protein 
subunits that carry out two main functions. The rings at the end of proteasomes serve as gates 
that only allow proteins tagged for degradation by ubiquitination to enter. The inner rings are 
then composed of proteins with various proteolytic capabilities to break down the targeted, 
unwanted protein. 
 There are two primary kinds of proteasomes that exist in cells: constitutive and 
immunoproteasomes. In terms of structure, the two kinds of proteasomes are identical except for 
differences in 3 of the core subunits, leading to different catalytic activity. Most of what is 
known about the immunoproteasome concerns its role in producing peptides for antigen 
presentation by MHC class I proteins in the immune system. However, a number of studies have 
started to suggest a greater diversity of roles of the immunoproteasome. Enhanced induction of 
the immunoproteasome was demonstrated in neurons expressing a mutation for Huntington’s 
disease (Diaz-Hernandez, 2004). Studies of hematologic cancer patients showed greater mRNA 
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transcript levels of one of the immunoproteasome catalytic subunits compared to its subunit 
counterpart in constitutive proteasomes (Kuhn, 2007). 
 Immunoproteasomes have also been implicated in aging. It has been observed that longer 
lived species have increased immunoproteasome subunit expression (Pickering, 2015), 
suggesting that induction of immunoproteasomes could play a role in attenuating the aging 
process. In addition, there is reason to believe that Acarbose may alter immunoproteasome 
activity, which could partially account for the lifespan extension seen with treatment. mTOR 
complex I has been implicated in regulating elements of proteostasis (Quarles, 2015). One 
component of this is recent evidence also implicating mTOR complex I in the formation of 
immunoproteasomes (Yun, 2016). If Acarbose regulates mTOR, then it could also play a role in 
altering immunoproteasome levels and activity. 
 The impact of aging and Acarbose on both constitutive and immunoproteasome activity 
in the heart was therefore investigated using the Proteasome Constitutive Immuno-Subunit Elisa, 
or PROCISE method (Kirk, 2014). This assay measures the activity of one of the primary 
catalytic subunits in constitutive proteasomes, β5, and its immunoproteasome counterpart, β5i. 
Differential activity of these subunits could potentially suggest a role of proteostasis in the 
effects of aging and Acarbose treatment on the heart. 
 
Overview 
 The experimental goal of this research is to assess the impact of Acarbose on age-
associated declines in motor and cardiac function and delineate its molecular role in the aging 
process. It has been established that Acarbose improves longevity in mice, but the impact of 
Acarbose on healthspan has not been determined. To evaluate this, young control, old control, 
and old Acarbose treated mice underwent motor function testing, including measurements of grip 
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strength, balance/coordination, and exercise performance. These same mice then underwent 
conventional, Doppler, and strain echocardiography to detect any cardiac structural or functional 
changes due to age or Acarbose. Cardiac tissue was then harvested from these mice for 
molecular analysis using mass spectrometry and the PROCISE assay. The aim is for the 
outcomes of this project to help guide future research and applications of Acarbose as a potential 
aging intervention in humans. 
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METHODS 
Mouse Model 
 58 mice were provided for this study by the Glenn Foundation. The mice were an outbred 
strain (UMHET3) resulting from the following F1 cross: [BL/6 x Balb/c] females x [C3H x 
DBA] males. 17 mice, 9 males and 8 females, were aged 4 months on control, Purina 5LG6 diet. 
17 mice, 9 males and 8 females, were aged 22 months on control diet. 24 mice, 12 males and 12 
females, were aged 22 months on control diet for the first 8 months of life and on control diet 
supplemented with Acarbose at 1000ppm for the remaining 14 months. 
 
Forelimb Grip Strength Testing 
 Grip strength protocol was adapted from Justice et al., 2013 and was assessed using the 
Columbus Instruments Grip Strength Meter provided by the Frankel Cardiovascular Center 
Physiology and Phenotyping Core at the University of Michigan. Testing was randomized and 
performed blinded by Sean Louzon and Jonathan Herrera. All 58 mice had their forelimb grip 
strength measured with 5 trials per mouse. Testing occurred over a 5-day period between the 
hours of 8:00am and 12:00pm. Each mouse had all 5 of its trials occur in the same morning 
roughly 30 minutes apart. Grip strength was reported as kilograms of force and the average grip 
strength across the 5 trials for each mouse was analyzed. 
 
Acceleration and Endurance Rotarod Testing 
 Rotarod testing protocol was adapted from Justice et al., 2013 and was performed on the 
Columbus Instruments Dual Species Economex Rota-Rod provided by the Frankel 
Cardiovascular Center Physiology and Phenotyping Core at the University of Michigan. Testing 
was randomized and performed blinded by Sean Louzon and Jonathan Herrera. All 58 mice were 
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tested following an acceleration protocol with 3 trials per mouse. Acceleration testing took place 
over a 5-day period between the hours of 1:00pm and 4:00pm. Each mouse had all 3 of its trials 
occur in the same afternoon roughly 30 minutes apart. Mice were placed onto the rotarod set at 
4rpm and accelerated at 0.1rpm/s until falling off the rod. The time was recorded from the start 
of acceleration to the time the mice fell. The maximum trial for each mouse was used for 
analysis. 
 All the mice also underwent an endurance protocol with 1 trial per mouse. Endurance 
testing occurred over a 5-day period between the hours of 8:00am and 12:00pm. The average of 
the max acceleration trials was used to calculate the average max speed for each of the following 
groups: 4 month males, 4 month females, 22 month males, and 22 month females. Mice were 
placed onto the rotarod set at 4rpm and accelerated at 0.1rpm/s until they reached 25% of their 
group’s max speed. They then maintained this speed for 2 minutes. The mice were then 
accelerated again at 0.1rpm/s until they reached 50% of their max speed where they were held 
for 5 minutes. They were then accelerated at 0.1rpm/s to 75% of their max speed and held for 10 
minutes. They were then accelerated one final time at 0.1rpm/s to their max speed and 
maintained at this final speed. The time was recorded from the start of the first acceleration and 
ran continuously throughout the test. If a mouse fell prior to the start of the 10-minute period at 
75% of max speed, it was placed back on the rotarod. If a mouse fell 10 times prior to the 10-
minute period at 75% of max speed, the mouse’s test ended, and its time was recorded as the 
time of its 10th fall. If a mouse fell once during the first 2 minutes of the 10-minute period at 75% 
max speed, it was placed back on the rod. If a mouse fell twice during the first 2 minutes of the 
10-minute period at 75% max speed, the mouse’s test ended, and its time was recorded as the 
time of its 2nd fall. If a mouse fell after the first 2 minutes of the 10-minute period at 75% max 
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speed, the mouse’s test ended, and its time was recorded as the time of its fall. If a mouse 
reached 30 total minutes, its test ended and its time was recorded as 30 minutes. 
 
Echocardiography 
 Echocardiography was performed randomized and blinded on all 58 mice by research 
echocardiography sonographer Kimber Converso-Baran at the University of Michigan Frankel 
Cardiovascular Center Physiology and Phenotyping Core. The following protocol description 
was provided by Kimber Converso-Baran. 
 Induction of anesthesia was performed in an enclosed container filled with 5% isoflurane. 
After induction, the mice were placed on a warming pad to maintain body temperature. 1 – 1.5% 
isoflurane was supplied via a nose cone to maintain a surgical plane of anesthesia.  The hair is 
removed from the upper abdominal and thoracic area with depilatory cream.  ECG is monitored 
via non-invasive resting ECG electrodes. Transthoracic echocardiography was performed in the 
supine or left lateral position.  Two-dimensional, M-mode, Doppler and tissue Doppler 
echocardiographic images were recorded using a Visual Sonics’ Vevo 2100 high resolution in 
vivo micro-imaging system. We measured LV ejection fraction from the two-dimensional long 
axis view.  In addition, we measured systolic and diastolic dimensions and wall thickness by M-
mode in the parasternal short axis view at the level of the papillary muscles. Diastolic function 
was assessed by conventional pulsed-wave spectral Doppler analysis of mitral valve inflow 
patterns (early [E] and late [A] filling waves). Doppler tissue imaging (DTI) was used to measure 
the early (E’) and late (A’) diastolic tissue velocities of the septal and lateral annuluses of the 
mitral valve in the apical 4-chamber view. Speckle-tracking strain was also utilized to evaluate 
subtle abnormalities in myocardial dysfunction.  
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Mass Spectrometry 
 Mass spectrometry was carried out by the Proteomics Resource Facility through the 
Department of Pathology at the University of Michigan. Protein sample preparation from frozen 
left ventricular heart tissue was performed by Sean Louzon using RIPA Buffer and Roche 
Complete Mini protease inhibitor cocktail tablets. Proteomic analysis was performed using 
Thermo Scientific TMT10plex Mass Tag Labeling Kits and Reagents. 27 samples were analyzed 
across 3 independent experiments, with each experiment containing 9 samples and 1 master-mix 
sample containing a small amount of all 27 samples. All samples sent for mass spectrometry 
were from male mice: 9 young controls, 8 old controls, and 10 old Acarbose treated. The 
following summarized protocol was adapted from the instructions manual for Thermo Scientific 
TMT10plex Mass Tag Labeling Kits and Reagents (a more detailed protocol can be found in the 
instructions manual). 
 Protein extracts were provided to the core and were then reduced, alkylated, and digested 
overnight. Samples are labeled with the TMT reagents and then mixed before sample 
fractionation and clean-up. Labeled samples are analyzed by high resolution Orbitrap LC-
MS/MS before data analysis to identify peptides and quantify reporter ion relative abundance. 
 A preliminary analysis of the mass spectrometry data was performed with independent 
sample t-tests to identify differentially expressed proteins with age and Acarbose treatment. 
Significance threshold for differential expression with age was set at p<0.001 and at p<0.01 for 
differential expression with Acarbose. More robust data analysis that accounts for multiple 
comparisons is currently being performed. 
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PROCISE Assay 
 Frozen left ventricular heart samples from all mice were sent to Ping Wang MD at the 
Feinstein Institute for Medical Research to perform the PROCISE assay. The protocol for the 
assay was adapted from Kirk et al., 2014. 
 
RNA Sequencing 
 RNA was prepared from left ventricular cardiac tissue from young control, old control, 
and old Acarbose treated mice using RNeasy Fibrous Tissue Mini Kit from Qiagen. RNA 
samples were sent to the DNA Sequencing Core at the University of Michigan for quality 
checks. All samples that had an RIN value greater than 6.5, a 260/280 ratio between 1.7 and 1.9, 
and a 260/230 ratio greater than 1.5 were subsequently sent for RNA sequencing at the core. 
 
Statistical Analysis 
 The overall effects of age and Acarbose treatment on each parameter were calculated 
with 2-way ANOVA’s using SPSS. When sex specific differences were present, individual group 
comparisons were calculated using independent samples t-tests.  
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RESULTS 
Acarbose Ameliorates Declines in Motor Function with Age 
 In addition to weighing the mice before testing began, the first set of healthspan measures 
conducted on the mice included grip strength, acceleration testing, and endurance testing. For 
both males and females, body weight was significantly increased with age and reduced with 
Acarbose (Figure 4A). Grip strength, which was normalized to body weight, was markedly 
impaired in 22 month controls compared to 4 month controls, and this was partially rescued by 
Acarbose treatment (Figure 4B). Significant effects of age and Acarbose on grip strength were 
still present without normalization to body weight (data not shown). 
 Acceleration testing, a reported measure of balance and coordination, was also performed 
in all mice. Fall latency in young controls was found to be greater than in old control males and 
females, indicating a decline in performance with age (Figure 4C). Acarbose treated old mice 
displayed greater fall latency than old controls in both sexes, again indicating a partial rescue in 
performance with Acarbose.  
 The final motor function test conducted was the endurance rotarod protocol which is 
suggested to represent a measure of exercise performance. While no statistically significant 
effects were found related to age or Acarbose treatment, there was a trend toward a reduction in 
fall latency with age and improvement with Acarbose in males and females (Figure 4D). 
Together, these tests help verify age-associated impairments in motor function and demonstrate 
that Acarbose can successfully restore functional ability to a more youthful state in mice. 
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Figure 4. Dot plots for body weight (A), grip strength (B), acceleration testing (C), and endurance testing (D). Circles represent 
data points for individual animals, horizontal black bars indicate the mean of the group, and error bars are ± standard error of the 
mean. No sex specific effects were found. Overall effects of age and Acarbose for each parameter are displayed above the 
corresponding dot plots with significance threshold set at p<0.05. 
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Male Specific Reduction in Concentric Left Ventricular Hypertrophy by Acarbose 
 Following motor function testing, all mice underwent conventional echocardiography to 
measure any changes in cardiac structure that occurred with age or Acarbose treatment. Left 
ventricular mass was found to be significantly increased in both males and females, but to a 
greater extent in males (Figure 5A). This is indicative of age-related ventricular hypertrophy, one 
of the hallmarks of the cardiac aging phenotype. Acarbose was successfully able to abrogate 
hypertrophy, but only in males. The effects of age and Acarbose on left ventricular mass are 
diminished when normalized to body weight (data not shown). 
 To further characterize the hypertrophy seen with age, measurements were obtained of 
the thickness of the posterior (Figure 5B) and septal (Figure 5C) walls of the left ventricle. Both 
parameters were shown to be significantly increased with age in males, but not in females. This 
demonstrates that, in at least males, the hypertrophy seen in the left ventricle is concentric, 
meaning it is due to increased thickness of the chamber walls. This is the same kind of 
hypertrophy that is typically reported in elderly patients. However, Acarbose did not 
significantly affect either wall thickness measurement. It is therefore possible that in males, the 
reduction in left ventricular mass with Acarbose is due to subtle declines in muscle thickness 
throughout the ventricle that are not significant individually but together result in significantly 
reduced left ventricular mass. Overall, this represents the first evidence that Acarbose 
ameliorates age-related concentric hypertrophy of the left ventricle in male mice. 
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Figure 5. Dot plots for left ventricular mass (A), posterior wall thickness (B), and septal wall thickness (C). Circles represent 
data points for individual animals, horizontal black bars indicate the mean of the group, and error bars are ± standard error of the 
mean. Sex specific effects are shown within the graphs. Where effects are not sex specific, overall effects for each parameter are 
displayed above the corresponding dot plots with significance threshold set at p<0.05. 
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Age-Associated Cardiac Functional Declines Not Detected 
 Given the left ventricular hypertrophy detected with age in our mice, our next question 
was whether these structural changes resulted in any cardiac functional declines. Functional 
parameters were assessed with both conventional and Doppler echocardiography. 
 Several measures of diastolic function, or the heart’s ability to properly relax following 
contraction, were measured including isovolumic relaxation time (Figure 6A) and the ratio of 
early to late ventricular filling (Figure 6B). However, no diastolic parameters were found to be 
significantly affected by either age or Acarbose treatment. This was also found to be true for 
myocardial performance index (Figure 6C), a combined measure of the left ventricle’s systolic 
(contractile) and diastolic function. The only parameter that demonstrated significant change was 
ejection fraction (systolic measure), which was shown to be increased with age in males (Figure 
6D). This change in ejection fraction however is not indicative of cardiac dysfunction. Based on 
the cardiac aging phenotype hallmarks, we expected to see age-related declines in diastolic 
function with preserved systolic function. However, we were not able to detect any cardiac 
functional deficits in our mice or any Acarbose-induced functional changes. 
 
 
A 
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Figure 6. Dot plots for IVRT (A), E’/A’ (B), MPI (C), and ejection fraction (D). Circles represent data points for individual 
animals, horizontal black bars indicate the mean of the group, and error bars are ± standard error of the mean. Sex specific effects 
are shown within the graphs. Where effects are not sex specific, overall effects for each parameter are displayed above the 
corresponding dot plots with significance threshold set at p<0.05. 
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Strain Echocardiography Reveals no Cardiac Dysfunction with Age 
 With no indications of cardiac dysfunction in our aged mice or any impacts of Acarbose 
treatment from conventional and Doppler echocardiography, we then looked to our strain data, 
which could potentially reveal more subtle abnormalities that would be otherwise undetected. 
We obtained measures of radial strain and strain rate in short axis and long axis orientations in 
addition to circumferential strain and strain rate in the short axis and longitudinal strain and 
strain rate in the long axis. 
 Of all the parameters analyzed, the only ones that showed any significant changes were 
circumferential strain and strain rate (Supplemental Figure 1). Both measures demonstrated no 
effect of Acarbose but were significantly increased with age in females. An increase in strain or 
strain rate in any orientation is indicative of improved contractile function, where a decrease 
suggests systolic dysfunction. We were therefore still not able to detect any cardiac dysfunction 
in our aged mice or any effect of Acarbose on cardiac functional parameters. 
 
 
 
 
 
 
 
 
 
 
Figure 7. Summary of findings from all echocardiography measurements. Significant parameters are bolded with significance 
threshold set at p<0.05. 
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A Potential Role of Metabolism in Cardiac Aging 
 Even though we were not able to directly identify any deficits in cardiac function with 
age or any functional effects of Acarbose, we did detect age-related left ventricular hypertrophy 
that was ameliorated with Acarbose treatment in males. This suggests that there could potentially 
be molecular cardiac changes that precede overt dysfunction.  
 Mass spectrometry on left ventricular cardiac tissue was therefore performed to detect 
differentially expressed proteins between 4 month control and 22 month control samples and 
between 22 month control and 22 month Acarbose treated samples. As a preliminary analysis of 
the data, independent sample t-tests were performed on each identified protein to determine if 
age or Acarbose treatment resulted in differential expression. Differentially expressed proteins 
were then categorized based on molecular function into one of four categories: metabolism, 
structural, cell signaling, or cell homeostasis (Figure 8). The proteins that demonstrate age-
related changes in expression are involved in all four functional categories, but the largest group 
of differentially expressed proteins are metabolic. Very few proteins that were upregulated with 
age were downregulated with Acarbose treatment, and no proteins were identified that were 
downregulated with age and upregulated with Acarbose. This preliminary analysis is being 
followed up by more robust statistical testing that accounts for multiple comparisons, yet this 
initial evaluation of the data suggests a potential role of metabolism in cardiac aging. No 
evidence currently exists to suggest that Acarbose might reverse any of these age-related 
metabolic changes. 
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Catalytic Activity Levels of the Constitutive Proteasome Decline with Age 
 To further investigate the molecular effects of Age and Acarbose treatment on the heart, 
the PROCISE assay was performed to assess the activity levels of a catalytic subunit of the 
constitutive (β5) and immunoproteasomes (β5i). Catalytic activity of the constitutive proteasome 
subunit, β5, was found to be reduced in 22 month controls compared to 4 month controls. No 
effect of Acarbose was detected on β5 activity. In addition, neither age nor Acarbose treatment 
demonstrated a significant effect on activity of the immunoproteasome catalytic subunit, β5i. 
These findings indicate that a decline in proteostasis in the heart with age could be taking place 
in the form of reduced proteasome activity, but no evidence suggests a role of Acarbose in 
abrogating this process.  
Figure 8. Summary of the preliminary analysis of mass spectrometry data by independent sample t-tests. Significance threshold 
for differential expression with age was set at p<0.001 and at p<0.01 for differential expression with Acarbose treatment.  
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Figure 6. Dot plots for relative β5 (A) and β5i (B) activity. Circles represent data points for individual animals, horizontal black 
bars indicate the mean of the group, and error bars are ± standard error of the mean. Overall effects for each parameter are 
displayed above the corresponding dot plots with significance threshold set at p<0.05. 
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DISCUSSION 
Conclusion 
 This thesis has demonstrated that Acarbose, in addition to extending lifespan, also 
ameliorates age-associated deficits in motor function and reduces left ventricular hypertrophy in 
males. These age-related effects could potentially be due to changes in cardiac metabolism with 
aging. However, no evidence indicates that the beneficial effects of Acarbose are a result of 
changes in cardiac metabolism or proteasome activity. The findings of this study further the 
promise of Acarbose as a potential aging intervention, but a lot of research is still needed before 
it could become a prescribed drug outside of diabetic patients. 
 
Functional Healthspan Testing 
 The results of the motor function tests were promising in that they demonstrated 
abrogation in age-associated deficits with Acarbose treatment. Each of the performed tests 
measure a specific parameter, such as balance and coordination for the acceleration test and 
exercise performance for the endurance test. It is important to recognize that both rotarod 
protocols and grip strength testing can be heavily influenced by the motivation of the animal to 
perform the tasks. However, we observed a significant decrement in performance with aging, 
consistent with published literature. Improvement in rotarod performance with Acarbose 
treatment demonstrates that Acarbose enhances functional health. 
 All 3 of the functional tests performed in this study are affected by multiple variables, but 
the one that is arguably the most controlled is grip strength. Since this test demonstrated the most 
robust effect of Acarbose treatment, a logical follow-up experiment would be to look at the 
impact of Acarbose on skeletal muscle. Our lab is currently planning to investigate this through 
RNA sequencing of the quadriceps or gastrocnemius from Acarbose treated mice. 
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 Along with functional health, another important quality of life measure that declines with 
age that this study did not address is learning and memory. The effect of Acarbose on cognition 
has not been described, and this is an interesting area of future research that would further 
characterize the role of Acarbose at ameliorating declines in healthspan with age. 
 
Lack of Age-Related Cardiac Dysfunction 
 Echocardiography was used in this study partially because it had previously been 
demonstrated to show age-related declines in a mouse model. It was therefore a surprise when 
we were not able to detect cardiac diastolic dysfunction in our aged mice. One possible 
explanation for this is that our mice may not have been old enough to develop any cardiac 
dysfunction. Previous studies reporting declines in cardiac function with age in mice have used 
mice at 21 months of age (Qin, 2013), while others have used mice at 24 months (Dai, 2009) or 
even older. The decision to have 22 months serve as the “old” timepoint in this experiment was 
based on considerations of attrition of the cohort. It is possible that echocardiography performed 
at a later timepoint may have found significant declines in cardiac function that could potentially 
have been impacted by Acarbose treatment. However, it is notable that all our testing was 
performed in a blinded fashion, and this rigorous methodology could also explain the 
discrepancy between our results and others previously published. 
 Another variable that could have caused us not to detect any age-related cardiac 
dysfunction is the strain of mice used in this study. Studies previously reporting cardiac 
dysfunction in aged mice have used inbred strains, where this project utilized an outbred mouse 
model. If changes in cardiac function with age significantly vary across strains, then it is possible 
that outbred mice could be less likely to detect age-related declines in function.  
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Male-Specific Cardiac Effects of Acarbose 
 Even though the effects of Acarbose on the heart were limited to reduction of left 
ventricular hypertrophy, it is notable that this effect was seen only in males. The reason behind 
this sexual dimorphism is not completely established, but a recent study has demonstrated that 
male-specific effects of Acarbose are associated with increased insulin sensitivity and greater 
glucose tolerance. It is possible that this differentiation can be explained by gonadal hormones, 
as castrated males show fewer metabolic responses to drug treatment than intact males (Garratt, 
2017). If Acarbose has limited beneficial effects in females, this could potentially hinder its 
translation value as an aging intervention, but more research is needed to address this. 
 
Cardiac Metabolism and Aging 
 The preliminary finding that changes in cardiac metabolism occur with age are 
promising, as this was expected based on previously published literature. It is also intriguing 
because of the role of Acarbose in glucose metabolism, which suggests that Acarbose could 
potentially alter the age-associated metabolic changes seen in the heart. This effect of Acarbose 
was not detected through our preliminary analysis, but more robust statistical analysis is being 
performed that will potentially provide us with a more definitive description of the role of 
metabolism in cardiac aging. 
 
RNA Seq to Further Explore the Molecular Roles of Aging and Acarbose in the Heart 
 Even before changes at the protein level, one of the first markers indicative of future 
dysfunction can be differential gene expression. RNA sequencing was performed on cardiac 
tissue from young control, old control, and old Acarbose treated mice. This sequencing is 
completed and is in the process of being analyzed. Detecting changes in gene expression with 
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aging or Acarbose treatment would offer further insight into the molecular mechanisms of 
cardiac aging. 
 
Proteostasis in Cardiac Disease and Beyond 
 While no effects of Acarbose on proteasome activity were found, it does not mean that 
Acarbose has no impact on proteostasis. Additional experiments need to be conducted to explore 
the effect of Acarbose on other elements of protein homeostasis such as synthesis and folding. 
 The decline in constitutive proteasome activity in the heart with age also needs to be 
further investigated to understand its role in cardiac health. It is possible that reduced proteasome 
activity could lead to an accumulation of misfolded or unneeded proteins in the heart. This could 
therefore result in protein aggregation that could cause age-related cardiac disease, but this 
cannot be concluded from the current study. 
 Understanding the role of proteostasis with age is critical beyond the scope of the heart. 
Neurodegenerative diseases including Alzheimer’s Disease are age-dependent and are often 
characterized by plaques or other forms of pathologic protein aggregation. Continued research 
into the connections between age and impairments in protein homeostasis is therefore essential. 
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Supplemental Figure 1. Dot plots for strain echocardiography data. Circles represent data points for individual animals, 
horizontal black bars indicate the mean of the group, and error bars are ± standard error of the mean. Sex specific effects are 
shown within the graphs. Where effects are not sex specific, overall effects for each parameter are displayed above the 
corresponding dot plots with significance threshold set at p<0.05. 
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